Who are 7vPnC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Prevnar 20, MenACWY, Meningitec®, Mencevax® ACWY, Vi-TT, MCV4.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/7vpnc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

7vPnC — Competitive Intelligence Brief

7vPnC (7vPnC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: conjugate vaccine. Area: Infectious Diseases.

phase 3 conjugate vaccine Infectious Diseases Biologic Live · refreshed every 30 min

Target snapshot

7vPnC (7vPnC) — Wyeth is now a wholly owned subsidiary of Pfizer. 7vPnC is a vaccine that protects against meningococcal disease caused by serogroups B and Y.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
7vPnC TARGET	7vPnC	Wyeth is now a wholly owned subsidiary of Pfizer	phase 3	conjugate vaccine
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
MenACWY	MenACWY	LimmaTech Biologics AG	marketed	Conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
Meningitec®	Meningitec®	GlaxoSmithKline	marketed	Conjugate vaccine	Neisseria meningitidis serogroup C polysaccharide capsule
Mencevax® ACWY	Mencevax® ACWY	GlaxoSmithKline	marketed	Conjugate vaccine
Vi-TT	Vi-TT	International Vaccine Institute	marketed	Typhoid conjugate vaccine	Salmonella typhi Vi polysaccharide antigen
MCV4	MCV4	CanSino Biologics Inc.	marketed	Meningococcal conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (conjugate vaccine class)

Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 7vPnC — Competitive Intelligence Brief. https://druglandscape.com/ci/7vpnc. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab